BioSight
Companies
Spyre Therapeutics, Inc. logo

SYRE

NASDAQWALTHAM, MA
Spyre Therapeutics, Inc.

Spyre Therapeutics develops biologic drug candidates to treat inflammatory and immune-mediated diseases, including inflammatory bowel disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Lead programs SPY001 and SPY002 are in Phase 2 clinical trials, with additional candidates in earlier development stages. The company is pursuing less frequent dosing schedules and combinations with other therapeutics to improve efficacy and convenience over existing treatments.

Price history not yet available for SYRE.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar